Related references
Note: Only part of the references are listed.Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH
Silvia Marchiano et al.
SCIENTIFIC REPORTS (2023)
Discovery of a Novel Class of Dual GPBAR1 Agonists-RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
Bianca Fiorillo et al.
ACS OMEGA (2023)
Discovery of FXR/PPAR? dual partial agonist
Yukiko Yamashita et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2023)
Structures of Leukotriene Biosynthetic Enzymes and Development of New Therapeutics
Jesper Z. Haeggstrom et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2023)
Combinatorial targeting of G-protein-coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug-induced liver injury
Michele Biagioli et al.
HEPATOLOGY (2023)
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Mary E. Rinella et al.
HEPATOLOGY (2023)
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease
Qiang Ren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2023)
A time- and space-resolved nuclear receptor atlas in mouse liver
Francesco Paolo Zummo et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2023)
Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists
Claudia Finamore et al.
MOLECULES (2023)
The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator
Varsha D. D. Shiragannavar et al.
FRONTIERS IN PHARMACOLOGY (2023)
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma
Cristina Di Giorgio et al.
FRONTIERS IN ONCOLOGY (2023)
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Ruben Nogueiras et al.
NATURE METABOLISM (2023)
Epoxylipids and soluble epoxide hydrolase in heart diseases
John D. Imig et al.
BIOCHEMICAL PHARMACOLOGY (2022)
Withaferin A in the Treatment of Liver Diseases: Progress and Pharmacokinetic Insights
Yangliu Xia et al.
DRUG METABOLISM AND DISPOSITION (2022)
Linking liver metabolic and vascular disease via bile acid signaling
Stefano Fiorucci et al.
TRENDS IN MOLECULAR MEDICINE (2022)
Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
Fangling Zhang et al.
FRONTIERS IN PHARMACOLOGY (2022)
Human gut bacteria produce TH17-modulating bile acid metabolites
Donggi Paik et al.
NATURE (2022)
Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease
Stefano Fiorucci et al.
FRONTIERS IN PHARMACOLOGY (2022)
The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice
Xiaoxin X. Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2022)
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Jingwei Cai et al.
PHARMACOLOGY & THERAPEUTICS (2022)
Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor
Bianca Fiorillo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Liver X receptors and liver physiology
Lillian Russo-Savage et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)
Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions
Patrick Campbell et al.
CLINICAL THERAPEUTICS (2021)
Lanifibranor and NASH resolution
Eleni Kotsiliti
Nature Reviews Gastroenterology & Hepatology (2021)
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M. Francque et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
DPP4 Activity, Hyperinsulinemia, and Atherosclerosis
Kaitlin M. Love et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action
Miguel Hernandez-Quiles et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Development and in vitro Profiling of Dual FXR/LTA4H Modulators
Simone Schierle et al.
CHEMMEDCHEM (2021)
The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease
Stefano Fiorucci et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Bile acids and their receptors in metabolic disorders
Stefano Fiorucci et al.
PROGRESS IN LIPID RESEARCH (2021)
Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics
Moritz Helmstadter et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
(E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells
Alzbeta Stefela et al.
FRONTIERS IN PHARMACOLOGY (2021)
Meta-analysis and Consolidation of Farnesoid X Receptor Chromatin Immunoprecipitation Sequencing Data Across Different Species and Conditions
Emilian Jungwirth et al.
HEPATOLOGY COMMUNICATIONS (2021)
Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
Binu V. John et al.
HEPATOLOGY COMMUNICATIONS (2021)
Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice
Moritz Helmstadter et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
Shizuya Yamashita et al.
CURRENT ATHEROSCLEROSIS REPORTS (2020)
A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice
Pascal Heitel et al.
COMMUNICATIONS CHEMISTRY (2020)
Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States
Zobair M. Younossi et al.
HEPATOLOGY (2019)
A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice
Md. Abdul Hye Khan et al.
BIOCHEMICAL PHARMACOLOGY (2019)
MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus
James Meixiong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation
Adriana Carino et al.
NUTRIENTS (2019)
Glucagon-like peptide 1 (GLP-1)
T. D. Mueller et al.
MOLECULAR METABOLISM (2019)
Bile acid metabolites control TH17 and Treg cell differentiation
Saiyu Hang et al.
NATURE (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
Eloy D. Hernandez et al.
HEPATOLOGY COMMUNICATIONS (2019)
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Xiaoxin X. Wang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Nadia Bougarne et al.
ENDOCRINE REVIEWS (2018)
Farnesoid X receptor modulators 2014-present: a patent review
Valentina Sepe et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Insights into the Role of PPARβ/δ in NAFLD
Jiapeng Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology
Simone Schierle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice
Cen Xie et al.
DIABETES (2017)
RORγ antagonists and inverse agonists: a patent review
Sarah M. Bronner et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
The Role of Sphingosine 1-Phosphate Receptor 2 in Bile-Acid-Induced Cholangiocyte Proliferation and Cholestasis-Induced Liver Injury in Mice
Yongqing Wang et al.
HEPATOLOGY (2017)
A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice
Xiaoxin X. Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis
Michele Biagioli et al.
JOURNAL OF IMMUNOLOGY (2017)
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis
Jurema Schmidt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease
Takako Mukai et al.
FEBS OPEN BIO (2017)
Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists
Simona De Marino et al.
SCIENTIFIC REPORTS (2017)
BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis
Adriana Carino et al.
SCIENTIFIC REPORTS (2017)
The role and regulation of the peroxisome proliferator activated receptor alpha in human liver
Sander Kersten et al.
BIOCHIMIE (2017)
Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet Cells to Promote Glucose Homeostasis
Divya P. Kumar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ
Nguan Soon Tan et al.
PROGRESS IN LIPID RESEARCH (2016)
Anthranilic acid derivatives as nuclear receptor modulators-Development of novel PPAR selective and dual PPAR/FXR ligands
Daniel Merk et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
Kristine Griffett et al.
MOLECULAR METABOLISM (2015)
Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
Aravind Sosale et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2015)
Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides
Cristina Lopez-Vicario et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
5-Lipoxygenase and cysteinyl leukotriene receptor 1 regulate epidermal growth factor- induced cell migration through Tiam1 upregulation and Rac1 activation
Shigeyuki Magi et al.
CANCER SCIENCE (2014)
The First Approved Agent in the Glitazar's Class: Saroglitazar
Ritesh Agrawal
CURRENT DRUG TARGETS (2014)
Design, Synthesis, and Biological Evaluation of Potent Dual Agonists of Nuclear and Membrane Bile Acid Receptors
Claudio D'Amore et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands
Carmen Festa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Modification on Ursodeoxycholic Acid (UDCA) Scaffold. Discovery of Bile Acid Derivatives As Selective Agonists of Cell-Surface G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1)
Valentina Sepe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
PHYSIOLOGICAL FUNCTIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR β
Jaap G. Neels et al.
PHYSIOLOGICAL REVIEWS (2014)
Cysteinyl leukotrienes and their receptors: Bridging inflammation and colorectal cancer
Sayeh Savari et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Semisynthetic Bile Acid FXR and TGR5 Agonists: Physicochemical Properties, Pharmacokinetics, and Metabolism in the Rat
Aldo Roda et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Bart Staels et al.
HEPATOLOGY (2013)
Identification of GPR99 Protein as a Potential Third Cysteinyl Leukotriene Receptor with a Preference for Leukotriene E4 Ligand
Yoshihide Kanaoka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Decoding Signaling and Function of the Orphan G Protein-Coupled Receptor GPR17 with a Small-Molecule Agonist
Stephanie Hennen et al.
SCIENCE SIGNALING (2013)
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity
Fei Li et al.
NATURE COMMUNICATIONS (2013)
Targeting Orphan Nuclear Receptors for Treatment of Metabolic Diseases and Autoimmunity
Thomas P. Burris et al.
CHEMISTRY & BIOLOGY (2012)
Conicasterol E, a Small Heterodimer Partner Sparing Farnesoid X Receptor Modulator Endowed with a Pregnane X Receptor Agonistic Activity, from the Marine Sponge Theonella swinhoei
Valentina Sepe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis
Barbara Renga et al.
PLOS ONE (2012)
4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity
Simona De Marino et al.
STEROIDS (2012)
Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity
Janne Prawitt et al.
DIABETES (2011)
Theonellasterols and Conicasterols from Theonella swinhoei. Novel Marine Natural Ligands for Human Nuclear Receptors
Simona De Marino et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Discovery of Sulfated Sterols from Marine Invertebrates as a New Class of Marine Natural Antagonists of Farnesoid-X-Receptor
Valentina Sepe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The Benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-α/γ Inverse Agonist
Naresh Kumar et al.
MOLECULAR PHARMACOLOGY (2010)
Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist
Giovanni Rizzo et al.
MOLECULAR PHARMACOLOGY (2010)
Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver
Manu V. Chakravarthy et al.
CELL (2009)
Molecular Characterization of Novel and Selective Peroxisome Proliferator-Activated Receptor α Agonists with Robust Hypolipidemic Activity in Vivo
Christopher D. Kane et al.
MOLECULAR PHARMACOLOGY (2009)
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
Masato Furuhashi et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Signaling by the cysteinyl-leukotriene receptor 2 -: Involvement in chemokine gene transcription
Charles Thompson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends
Valerie Capra et al.
MEDICINAL RESEARCH REVIEWS (2007)
T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXR
Nico Mitro et al.
FEBS LETTERS (2007)
20-Carboxy-arachidonic acid is a dual activator of peroxisome proliferator-activated receptors alpha and gamma
Xiang Fang et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
Cysteinyl-leukotriene receptors and cellular signals
G. Enrico Rovati et al.
THESCIENTIFICWORLDJOURNAL (2007)
Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network
Angie L. Bookout et al.
CELL (2006)
Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats
J Fu et al.
NEUROPHARMACOLOGY (2005)
T0901317 is a dual LXR/FXR agonist
KA Houck et al.
MOLECULAR GENETICS AND METABOLISM (2004)
Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity
YX Wang et al.
CELL (2003)
A G protein-coupled receptor responsive to bile acids
Y Kawamata et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Selective interaction of bile acids with muscarinic receptors: a case of molecular mimicry
JP Raufman et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist
KR Cheng et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
R Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonists
JP Raufman et al.
PHARMACOLOGY (2002)
Vitamin D receptor as an intestinal bile acid sensor
M Makishima et al.
SCIENCE (2002)
Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
S Fiorucci et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38
LV Madrid et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity
JL Staudinger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
